The preparation is used across therapeutic domains where short-term symptomatic support is needed for heightened patient distress: the management of anxiety-related tension and the relief of severe allergic itching. It provides symptomatic assistance relevant in clinical settings marked by disruptive symptom manifestations.

The medication is commonly used to help with a brief listing of indications including: symptomatic relief of anxiety and tension, management of intense pruritus associated with chronic urticaria or allergic dermatoses, and use as a sedative support in certain medical procedures. Applied across therapeutic domains where short-term symptom management is appropriate, it provides relief for symptom clusters that interfere with daily comfort.

“The supportive benefit may include assisting patients during difficult episodes by easing the overall symptom burden related to nervousness or persistent skin discomfort.”

---

Quick Fact: Relief for Key Symptom Domains

Symptom Domain	Practical Benefit
Emotional Tension	Contributes to easing distress and managing symptoms related to worry and restlessness.
Severe Pruritus (Itching)	Contributes to improved comfort during symptomatic periods.
Sleep Disturbance	Provides supportive relief when symptoms interfere with routine activities.

Regulatory References

1. NIH MedlinePlus Drug Information overview on Hydroxyzine

Eligibility Map: Who can and cannot use Hydroxyzinum Aflofarm — Official Regulatory Information

The eligibility profile for Hydroxyzinum Aflofarm is defined by absolute contraindications and restrictions based on cardiac status, age, and organ function, as established in regulatory documents.

---

Eligibility Category	Key Regulatory Rule / Population
Contraindicated Populations	Known hypersensitivity to hydroxyzine, cetirizine, or piperazine derivatives.
	Patients with known QT interval prolongation or risk factors for cardiac arrhythmia.
	Pregnancy (early trimester) and Lactation (Breastfeeding).
Age-Related Restrictions	Older Adults (Geriatric) use is generally not recommended; the maximum daily dose is restricted if use is unavoidable.
	Children under 6 years of age are generally not recommended for the tablet form.
Condition Restrictions	Use requires caution in patients with moderate to severe renal or hepatic impairment.
	Use requires caution in conditions susceptible to anticholinergic effects (e.g., glaucoma, urinary retention).

---

Connection to the overall eligibility profile:

Official regulatory documents establish stringent rules that define the eligible population, with absolute prohibitions based on cardiac safety and hypersensitivity, and strict limitations based on age and organ function. These regulatory criteria determine that most healthy adults are eligible under standard conditions, while excluding specific populations due to recognized, officially documented safety concerns.

Interactions with other medicines and products

Hydroxyzine’s official regulatory profile is defined by two primary interaction types: pharmacodynamic potentiation and specific cardiovascular risk. The use of this medicine is contraindicated with other medicinal products known to prolong the QT interval or induce Torsade de Pointes (TdP), including specific Class IA and Class III antiarrhythmics, certain antipsychotics, and certain antibiotics. This restriction is also extended to patients with a known acquired or congenital QT interval prolongation.

Interaction Scope Summary

Category	Regulatory Interaction Statement
Pharmacodynamic Interaction	Hydroxyzine exhibits a potentiating action with other Central Nervous System (CNS) depressants, such as narcotics, non-narcotic analgesics, hypnotics, and barbiturates, resulting in additive CNS depression.
Metabolic Interaction	Hydroxyzine is metabolized by the enzyme CYP3 A4/5. Co-administration with strong CYP3 A4/5 inhibitors is contraindicated, as this metabolic interaction leads to increased plasma concentrations and heightened cardiac risk.
Substance Restrictions	The simultaneous consumption of alcohol must be avoided due to the additive CNS depressant effect. Grapefruit or grapefruit-containing products are also restricted because of the risk of increased hydroxyzine exposure via CYP3 A4 inhibition.
Population-Specific Notes	The use of hydroxyzine is not recommended in elderly patients due to reduced elimination. Reduced dosage is required for patients with impaired hepatic or renal function due to the risk of drug accumulation.

Connection to the Overall Interaction Profile

Regulatory documents structure the product's interaction profile around preventing severe cardiovascular and CNS events. The two primary classes of interactions—CNS potentiation and metabolic inhibition leading to cardiac risk—dictate the mandatory contraindications and the required dose adjustments or avoidance of specific substances like alcohol and grapefruit products.

Hydroxyzinum Aflofarm exerts its action through multiple distinct receptor-mediated signaling pathways in the central and peripheral nervous systems. Its overall profile is determined by modulating key neurotransmitter systems, resulting in predictable physiological activity.

Histamine H1 Receptor Antagonism

This compound functions primarily as an inverse agonist at the histamine H1 receptors. By engaging this mechanism, it suppresses the activity of endogenous histamine, a key mediator involved in inflammatory signaling and neural arousal regulation. This action results in a physiological outcome of reduced mediator activity and influences neural signaling pathways in the central nervous system.

Subcortical Pathway Modulation

Within the central nervous system, the compound modulates pathways associated with heightened physiological responses. This is believed to occur through suppression of activity in certain subcortical areas, such as the reticular formation, which are integral to regulating general alertness and visceral functions. This mechanistic cascade contributes to modulating overactive responses, promoting a more regulated state within targeted neural pathways.

Secondary Receptor Interaction

The compound also engages in mechanisms involving other receptors, exhibiting weak antagonism at the serotonin 5-HT2A and muscarinic acetylcholine receptors. The influence on the serotonergic pathway may contribute to regulating signal transduction, while the anticholinergic property impacts the parasympathetic nervous system's function, including glandular output. This combined receptor engagement shapes the compound’s final pharmacodynamic profile.

How Hydroxyzinum Aflofarm is Used: Administration Guidelines

Hydroxyzine, the active component in this preparation, is used according to specific instructions which define its route, dosage, and duration of use.

---

Administration Parameter	General Instruction
Route of Administration	The primary route is Oral (tablets, syrup). The preparation is also used for Intramuscular (IM) Injection in acute clinical settings. The injectable solution is strictly prohibited for intravenous, subcutaneous, or intra-arterial administration.
Dosing Schedule	The total daily dose is typically administered in divided doses throughout the day. For pruritus (itching) in adults, a common starting regimen is 25 mg taken three to four times daily. Depending on the specific condition and regional guidelines, the maximum total daily dose may be established at 100 mg, though higher limits are sometimes cited for specific indications in adults.
Timing and Intake	Oral forms may be administered without regard to meals. Liquid forms must be measured using a calibrated device for accurate dosage.
Duration Mandate	The drug must be used at the lowest effective dose and for the shortest possible duration. For conditions like anxiety, the need for continued treatment must be reassessed periodically.

---

Population-Specific Dosing Rules

Dosage adjustments are specified for certain patient groups to maintain proper use:

• Older Adults: The maximum daily dose is generally restricted to 50 mg per day.
• Renal Impairment: For patients with moderate to severe kidney function impairment, the total daily dosage should be reduced by 50%.
• Hepatic Impairment: For patients with liver dysfunction, it is recommended that the total daily dose be reduced by 33%.

Note: Treatment must be suspended at least five days before allergy skin testing to prevent interference with test results.

Hydroxyzine: Clinical Evidence Summary

Clinical trials and evidence reviews support the use of hydroxyzine for its established indications, primarily involving its antihistamine and sedative properties.

Evidence in Anxiety and Sedation

Research has investigated the use of hydroxyzine as a non-benzodiazepine agent for managing generalized anxiety disorder (GAD) and anxiety associated with other conditions. Studies suggest that hydroxyzine may be an option for short-term management of acute anxiety symptoms. Its effect as a central nervous system depressant is also utilized for preoperative sedation; evidence confirms its ability to produce mild to moderate sedation and help manage apprehension before medical procedures.

---

Evidence in Pruritus and Urticaria

Hydroxyzine acts as an H1-receptor antagonist, which serves as the pharmacological basis for its use in treating itching (pruritus). Clinical data support its effectiveness in relieving itching associated with allergic conditions such as chronic urticaria (hives) and atopic and contact dermatoses. By blocking histamine release, it interrupts the cycle of histamine-induced itching and related skin reactions. Comparative studies often evaluate hydroxyzine against newer, less-sedating antihistamines, noting that hydroxyzine’s first-generation status means it carries a higher potential for sedation, which can be beneficial when pruritus disrupts sleep.

---

Key Observed Effects in Trials

Indication	Primary Observed Effect
Anxiety	Reduction in anxiety symptoms scores (e.g., Hamilton Anxiety Rating Scale).
Pruritus	Subjective and objective reduction in itching intensity and duration.
Sedation	Observed drowsiness and decreased apprehension (measured pre-surgery).

The overall evidence base emphasizes that the established utility of hydroxyzine is directly linked to its potent H1-antihistamine activity and central nervous system effects, particularly for short-term use in managing acute symptoms.

Key Studies & References

1. Hydroxyzine as a pre-operative sedative: a double blind study with apprehensive children

Common questions about Hydroxyzinum Aflofarm (FAQ)

---

Q: How quickly does Hydroxyzinum Aflofarm start working after a dose?

Official regulatory information indicates that the active substance starts to work relatively quickly after oral administration. The onset of clinical effects is generally described as occurring within 15 to 30 minutes of taking a dose.

---

Q: What is the expected duration of the effects of Hydroxyzinum Aflofarm?

The immediate therapeutic effects described in official sources, such as calming or anti-itch actions, generally range from approximately 4 to 6 hours. However, regulatory information notes that the medicine takes significantly longer to be fully eliminated from the body.

---

Q: Does taking Hydroxyzinum Aflofarm with food change how it is absorbed?

According to the official product information, oral forms of the medicine may be taken without concern for meals. Some official advice mentions that taking the medicine with food may potentially help reduce the possibility of an upset stomach.

---

Q: Can Hydroxyzinum Aflofarm cause headaches or blurred vision?

Headache is listed in regulatory documents as a common side effect of the medicine. Blurred vision has also been reported in official adverse reaction summaries as a possible adverse effect.

---

Q: Are there specific types of over-the-counter pain relievers that interact with Hydroxyzinum Aflofarm?

Official documents warn about a potentiating action with central nervous system (CNS) depressants, which can include certain non-narcotic pain relievers. The combination can lead to increased drowsiness or sedation. Regulatory documents suggest being aware if any co-administered medicine has a CNS depressant effect.

---

Q: Can Hydroxyzinum Aflofarm interact with common stomach medications, such as antacids?

Official product information does not specifically list antacids as a major interaction. However, the medicine has anticholinergic properties that can affect glandular function, which is noted in regulatory documents.

---

Q: Does Hydroxyzinum Aflofarm have an effect on blood pressure?

Regulatory adverse reaction reports include hypotension (low blood pressure) as a rare event. Official information also indicates that caution is advised for patients with pre-existing heart conditions.

---

Q: Is Hydroxyzinum Aflofarm classified as a central nervous system depressant?

Regulatory documents repeatedly refer to the medicine's ability to cause additive CNS depression when combined with other similar medicines. This indicates its recognized function as an agent with sedative properties.

---

Q: How long does the medicine stay in the body after the last dose is taken?

The half-life of the active substance in adults is approximately 14 to 25 hours. Pharmacokinetic data from regulatory summaries indicates that because the medicine requires several half-lives for complete removal, it may remain in the body for several days after the final dose.

---

Q: Are there reported instances of involuntary movements or tremors with Hydroxyzinum Aflofarm?

Involuntary motor activity, including rare instances of tremor and convulsions, has been reported in post-marketing experience. Regulatory reports suggest that these effects have been associated with, but not limited to, doses that were higher than recommended.

---

Q: What information is available about Hydroxyzinum Aflofarm and glaucoma?

Regulatory documents advise that the medicine must be used with caution in individuals who have or are at risk of conditions sensitive to anticholinergic effects, which includes glaucoma. The medicine may potentially worsen these conditions.

---

Q: Can a patient use Hydroxyzinum Aflofarm for difficulty sleeping, even if not prescribed for that specific reason?

The official uses of the medicine include treating anxiety and pruritus (itching). Regulatory information acknowledges that the medicine’s recognized sedative effects can aid in situations where sleep disturbance is linked to those primary conditions; however, it is not listed as an official indication for the primary treatment of sleep disorders.

---

Q: Is Hydroxyzinum Aflofarm considered a drug with risk of dependence or addiction?

Regulatory information indicates that the medicine is not classified as a controlled substance under the U.S. Controlled Substances Act and is not generally associated with the same potential for abuse or dependence as other controlled central nervous system depressants.

---

Q: Can Hydroxyzinum Aflofarm cause increased irritability or agitation in some people?

Official documents list agitation as an uncommon side effect. Regulatory reports have also noted other changes in thinking or behavior, such as aggressiveness, though these are typically rare events.

---

Q: Can Hydroxyzinum Aflofarm cause an upset stomach or nausea?

Nausea is listed in official documents as an uncommon side effect. Stomach upset and vomiting have also been reported in official post-marketing summaries, particularly in cases of overdosage.

---

Q: Is there research on Hydroxyzinum Aflofarm's use for chronic itching?

Yes, regulatory documents confirm that clinical evidence supports the use of the medicine for the management of pruritus (itching) associated with allergic skin conditions. This includes chronic conditions such as chronic urticaria (hives).

---

Q: Can the medicine be crushed or split if a patient has trouble swallowing?

The medicine is made available in multiple forms, including film-coated tablets and an oral solution (syrup). Regulatory information advises that the oral solution is available and must be accurately dosed using a calibrated device if a patient has difficulty swallowing.

---

Q: Is the time it takes for Hydroxyzinum Aflofarm to work the same for anxiety and itching?

Pharmacokinetic data shows that the active substance is rapidly absorbed, and the clinical effects generally begin within 15 to 30 minutes for both its anti-anxiety and antihistamine uses. Official studies note that the anti-itch effect may persist for a longer duration than the sedative effect.

---

Q: Is Hydroxyzinum Aflofarm considered a 'controlled substance'?

No, the medicine is not listed as a controlled substance under the U.S. Controlled Substances Act and is not scheduled by the Drug Enforcement Administration (DEA).

How to Store and Dispose of Hydroxyzinum Aflofarm?

Storage and disposal of this medicine must comply strictly with official regulatory requirements to ensure product quality and public safety.

Official Storage Conditions

Requirement Type	Condition
Temperature Limit	Store at a temperature that does not exceed 25°C (store below 25 C).
Container Integrity	The medicine must be kept in the original packaging.
Child Safety	Store the product out of the sight and reach of children.
Stability Rule	The medicine must not be used after the expiration date (EXP) printed on the label.

---

Disposal Instructions

Unused or expired Hydroxyzinum Aflofarm must not be thrown into household waste or wastewater. Proper disposal requires adhering to local regulations for pharmaceutical waste. Patients should consult a pharmacist for guidance on discarding medicines no longer needed, which is necessary for environmental protection.